Genmab — November 2020
-
-- TEPEZZA (teprotumumab-trbw) Third-Quarter 2020 Net Sales of $286.9 Million; Increasing Full-Year 2020 Guidance to Greater Than $800 Million from Greater Than $650 Million; Significantly Increasing Investment in TEPEZZA to Support Continued Strong Growth --
-
Pursuing TEPEZZA Expansion Outside the United States -- https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-reports-record-third-quarter-2020
-
the Dara- Duobodies combo-trial adds pomalidomide https://clinicaltrials.gov/ct2/history/NCT04108195?A=12&B=13&C=merged#StudyPageTop
-
5bn $, er det Horizons forventninger? Eller har du selv regnet dig frem til det Solsen?
-
Dit estimat lyder godt:-)
-
enmab
@Genmab
·
6 min
#ICMYI: Last week, we launched our website in Japan. Hear more from our CEO Jan van de Winkel on how we are expanding our presence in Japan with a goal to transform cancer treatment. http://genmab.co.jp -
Onsdag kan vi udregne % satsen, når Genmab har aflagt regnskab...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind